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Abstract
Background: The SLC39A14, SLC30A10 and SLC39A8 are considered to be key genes involved in manganese (Mn)
homeostasis in humans. Mn levels in plasma and urine are useful tools for early recognition of these disorders. We
aimed to explore further biomarkers of Mn deposition in the central nervous system in two siblings presenting with
acute dystonia and hypermanganesemia due to mutations in SLC39A14. These biomarkers may help clinicians to
establish faster and accurate diagnosis and to monitor disease progression after chelation therapy is administered.
Results: A customized gene panel for movement disorders revealed a novel missense variant (c.311G > T; p.Ser104Ile)
in SLC39A14 gene in two siblings presenting at the age of 10 months with acute dystonia and motor regression. Mn
concentrations were analyzed using inductively coupled mass spectrometry in plasma and cerebrospinal fluid, disclosing
elevated Mn levels in the index case compared to control patients. Surprisingly, Mn values were 3-fold higher in CSF than
in plasma. We quantified the pallidal index, defined as the ratio between the signal intensity in the globus pallidus and
the subcortical frontal white matter in axial T1-weighted MRI, and found significantly higher values in the
SLC39A14 patient than in controls. These values increased over a period of 10 years, suggesting the relentless pallidal
accumulation of Mn. Following genetic confirmation, a trial with the Mn chelator Na2CaEDTA led to a reduction in
plasma Mn, zinc and selenium levels. However, parents reported worsening of cervical dystonia, irritability and sleep
difficulties and chelation therapy was discontinued.
Conclusions: Our study expands the very few descriptions of patients with SLC39A14 mutations. We report for the first
time the elevation of Mn in CSF of SLC39A14 mutated patients, supporting the hypothesis that brain is an important
organ of Mn deposition in SLC39A14-related disease. The pallidal index is an indirect and non-invasive method that
can be used to rate disease progression on follow-up MRIs. Finally, we propose that patients with inherited defects of
manganese transport should be initially treated with low doses of Na2CaEDTA followed by gradual dose escalation,
together with a close monitoring of blood trace elements in order to avoid side effects.
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Background
Manganese (Mn) is a trace metal with a key role as a co-
factor of multiple enzymes, including hydrolases, lyases,
glycosyltransferases, arginase, glutamine synthase and
superoxide dismutase (SOD), in the synthesis of hor-
mones and neurotransmitters [1] and during inflamma-
tory events of the central nervous system [2].
Mn deposition in the brain can occur due to acquired
causes (such as environmental exposure), as well as inher-
ited defects in Mn transport and metabolism. Mn intoxi-
cation has been described in miners, welders, individuals
working or living near ferro-alloy factories or in those
drinking contaminated water, as well as in patients receiv-
ing total parenteral nutrition or those with acquired
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hepatocerebral degeneration [3]. Patients with severe Mn
exposure may develop an extrapyramidal syndrome
termed manganism, with rigidity, bradykinesia and dys-
tonia [3]. Mn dyshomoeostasis may also result from inher-
ited genetic defects in one of the transporters implicated
in Mn homeostasis, namely SLC39A8, SLC30A10 and
SLC39A14. Recently, several in vitro and in vivo models
have elucidated their role in the transport of Mn and other
divalent metals [2, 4–10]. SLC39A8 (MIM608732) encodes
ZIP8, a Mn and Zn transporter that localizes to the hep-
atocyte canalicular membrane and reclaims Mn from bile
[7]. Knock out ZIP8 mice showed markedly decreased Mn
levels in multiple organs and whole blood, increased bile
levels, and decreased activity of Mn-dependent enzymes,
such as arginase and β-1, 4-galactosyltransferase [7]. Bialle-
lic mutations in this gene lead to severe Mn depletion and
a secondary congenital disorder of glycosylation (CDG)
syndrome. Patients manifest developmental delay and
intellectual disability, dwarfism, craniosynostosis, cerebellar
atrophy, seizures and Leigh-like syndrome [11, 12].
SLC30A10 (also known as ZnT10) (MIM611146) and
SLC39A14 (also known as ZIP14) (MIM608736) are ef-
flux and influx transporters, respectively, that coopera-
tively regulate Mn homeostasis in humans. Recently, Liu
et al. 2017 generated knockout (KO) mice models lack-
ing SLC30A10, SLC39A14 and both transporters (double
knockouts) demonstrating high blood and brain Mn
levels in the three mice models, but only high liver Mn
levels in the single SLC30A10 KO model. These findings
are in agreement with those observed in patients with
recessive mutations in SLC30A10 and SLC39A14, show-
ing cerebral Mn deposition as a consequence of in-
creased systemic Mn load in both disorders [13], but
only polycythemia and liver cirrhosis in SLC30A10 [14].
Animal models demonstrated that SLC30A10 and
SLC39A14 localized to the canalicular and basolateral
domains of hepatocytes, respectively, thereby mediating
Mn biliary excretion synergistically [8]. Moreover,
SLC39A14 KO mice showed reduce Mn transport into
enterocytes at the basolateral membrane, thereby de-
creasing Mn excretion via the gastrointestinal tract [4].
Patients with SLC30A10 and SLC39A14 defects show a
progressive dystonia-parkinsonism syndrome as a conse-
quence of Mn toxicity to the basal ganglia. Chelation
therapy in both disorders increases Mn urinary excretion
and decreases plasma Mn concentrations with variable
clinical improvement [14–17]. SLC39A14 KO mice suf-
fer from Mn brain deposition and motor dysfunction,
thus recapitulating the disease in humans [4, 10].
In this study, we present two siblings with homozy-
gous SLC39A14 mutations causing hypermanganesemia,
progressive dystonia, severe disability and early death.
Our study reports a likely novel pathogenic variant in
SLC39A14, thereby expanding the reported mutations in
this gene. We examine the levels of Mn and other trace
elements in plasma and cerebrospinal fluid (CSF), as po-
tential biomarkers for diagnosis and treatment monitor-
ing. We also describe serial magnetic resonance imaging
(MRI) abnormalities over time, confirming progressive
changes with pallidal Mn deposition.
Methods
The index case was born to healthy consanguineous
Senegalese parents. Detailed delineation of the patient’s
history, disease course and clinical examination was
undertaken, as well as molecular genetics, radiological
and biochemical studies. Family history revealed a simi-
larly affected older brother for whom a stored DNA
sample was available. Parental DNA was also obtained.
The study was approved by the ethics committee at Sant
Joan de Déu Hospital and parents gave written informed
consent for study participation.
We also performed a literature review on genetic causes
of Mn dysregulation, by searching MEDLINE (through
PubMed) the following keywords: #1 SLC30A10, #2
SLC39A14, #3 SLC39A8, #4 hypermanganesemia and #5
manganese homeostasis. A total of 12 clinical studies were
finally selected (Table 1) [11, 12, 15–25].
Biochemical studies
CSF and plasma samples were analyzed with an Agilent
7500ce inductively coupled plasma mass spectrometer
(Agilent Technologies, Waldbronn, Germany). The instru-
ment uses a collision/reaction cell with hydrogen for sel-
enium (Se) determination, and helium for zinc (Zn) and
Mn. Briefly, after ionization of plasma or CSF samples in
the plasma torch and elimination of interference in the
collision/reaction cells, element concentrations were de-
termined by mass spectrometry, as previously reported
[26, 27]. Hemolysed plasma samples were excluded to
avoid blood contamination that can significantly increase
Zn and Mn values.
Plasma samples preparation: 25 μL of plasma samples
were diluted (1:40; V:V) in 25 μL of distilled water and
950 μL of a solution containing 0.7 mmol/L EDTA
(Merck, Darmstadt, Germany), 0.07% Triton-X-100
(Merck), 2% butanol, 0.5% ammoniac (Merck) and germa-
nium as internal standard (Merck).
CSF samples preparation: 50 μL of CSF samples were
diluted (1:20; V: V) in a 2% nitric solution and 10 μg/L
of germanium as internal standard (Merck).
MRI studies
The pallidal index (PI), defined as the ratio between the
signal intensity in the globus pallidus (SIGP) and the sub-
cortical frontal white matter (SIFW) in axial T1-weighted
MRI [28] was calculated in our patient on MRIs under-
taken at age 11 months, 8 and 10 years. Values were
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Table 1 Characteristics of patients with SLC30A10, SLC39A14, and SLC39A8 mutations
Phenotypes SLC30A10 SLC39A14 SLC39A8
Early-onset dystonia, polycythemia
and hepatopathy, adult-onset
parkinsonism and spastic paraparesis
Rapidly progressive childhood-
onset parkinsonism-dystonia
Type II congenital disorder of
glycosylation with Leigh syndrome
and autosomal recessive intellectual
disability with cerebellar atrophy
Number of patients reported 39 10 12
References [16–24] [15] current paper [11, 12, 25]
First described in 2000 2016 2015
Age at onset, median (IQR) 7.1 (1–57 years) 15.8 (7–36 months) Birth to 1 year of age
Sex 20F/19M 6F/4M 8F/4M
Death and cause 4 death (3 cirrhosis-related
complications and 1 pneumonia)
4 death (2 respiratory infections
and 2 unknown cause)
1 death (infection)
Parental Consanguinity (N) 34 10 10
Main neurological signs and
symptoms
Focal and generalized dystonia, gait





Other neurological signs and
symptoms
Central hypotonia, behavioral changes,
developmental delay, dysphagia, ataxia,









myoclonic seizures and infantile spasm
Abnormal head growth / skull
deformity
Normal head circumference Microcephaly (N = 4),
macrocephaly (N = 1),
Craniosynostosis (N = 1)
Normal head circumference,
craniosynostosis in 1 patient
Blood Mn levels (nmol/L) Increased
3345.7 ± 2575.3 (RV: <320)
Increased
2898 ± 2532(RV: <320)
Decreased
16.4 ± 5.8 (RV: 5.3–40.8)
Urinary Mn levels Increased
11.3 ± 4.8 mcg/L (RV: 0.5–4)
Not reported (increased in our
patient: 8.2 mcg/L; RV:0.4–0.9)
Increased
56.5 ± 73.2 nmol/L (RV: 1.3–9.1)
Systemic involvement and
others biochemical abnormalities
Hepatopathy: Hepatomegaly in 14
patients, liver cirrhosis in 8 patients
and increased transaminases in 41%:
ALT: 107.1 ± 50.7 (RV <55)
Polycythemia in 21% of patients:
haematocrit 52.8 ± 6.4% (RV: 34–40)
Not reported Dysmorphic featuresa, dwarfism with
short limbs and scoliosis
Increased transaminases in 2 patient
(AST: 441 UI/L (RV < 80), ALT: 102 and
113 UI/L (RV < 55)) and impaired blood
coagulation 1 patient
High blood lactate (8.7 mmol/L) and CSF
lactate (4.2 mmol/L) in 1 patient (RV: <1.9)
Abnormal glycosylation pattern in 7
patients









Cerebral white matter 10
T2 W hyperintensity
Basal ganglia 2
Brainstem atrophy 1 Diffuse cerebral and cerebellar
atrophy 4
Diffuse cerebellar atrophy 10
Frontal lobes atrophy 1
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compared to nine age-matched control patients. The
MRIs in control patients were obtained as part of a diag-
nostic protocol for patients with chronic headache, and
were classified as normal by expert neuroradiologists.
Genetic analysis
A customized gene panel for movement disorders was de-
sign by Sure Design Tool (Agilent Technologies, Santa
Clara, CA, USA). This panel included 78 genes causing
basal ganglia disease which were classified in four groups:
Aicardi-Goutières syndrome, thiamine metabolism, mito-
chondrial disorders and other neurometabolic disorders,
including SLC30A10 and SLC39A14 related to Mn dysreg-
ulation. Library construction was performed according to
manufacturer’s protocol using HaloPlex technology. Se-
quencing was carried out on MiSeq sequencer (Illumina,
San Diego, CA, USA). Data processing, variant calling and
variant annotation were done by DNAnexus platform and
Variant Studio software. The average of mean-coverage in
the sample gene panel was 95% for a read depth of 20X.
Filtering was performed by minor allele frequency < 1%
and possible pathogenicity based on mutation effects
(frameshift, insertions deletions, missense, stop gain and
splice site regions). Variant validation and segregation
studies were done by PCR with Sanger sequencing using
the Big Dye Terminator Cycle Sequencing System (Ap-
plied Biosystems). Primers for validation of the identified
change in SLC39A14 were forward primer 5’-GAAGGCT-




The proband was born from consanguineous healthy
Senegalese parents, after an uneventful pregnancy and de-
livery. He had a normal perinatal period and early neuro-
developmental milestones were on average. At 11 months
he developed acute generalized dystonia and neurological
regression following an intercurrent viral respiratory infec-
tion. On neurological examination there was evidence of
skull deformity with normal head circumference, dystonic
tetraparesis, oromandibular dystonia and opisthotonos. A
plain skull radiogram revealed multiple-suture craniosyn-
ostosis. Metabolic investigations in blood, CSF and urine
were normal at that moment, except for a mild decrease
in 5-hydroxyindolacetic acid concentrations (104 nmol/L,
reference values (RV): 170–490). The family moved to
Senegal and they returned to our hospital at the age
of 9 years. At this time, the patient had developed
microcephaly (head circumference 51 cm, 6th per-
centile), severe dystonic tetraparesis, anarthria, dys-
phagia and malnutrition. He required enteral tube
feeding and received baclofen, diazepam and gabapen-
tin for symptomatic control of dystonia.
On reviewing the family history, it became apparent that
there was a similarly affected older brother, born in 1997,
who developed acute dystonic tetraparesis associated with
rigidity, hypokinesia and pyramidal signs, following a viral
illness at the age of 10 months. Brain MRI revealed bilat-
eral pallidal T2-hypointensity and pallidal and cerebral
and cerebellar white matter T1-hyperintensity. His clinical
status remained unchanged until age 21 months, when he
died in Senegal of unknown cause.
The clinical picture of these siblings was analyzed in
the context of the existing literature on 46 patients pre-
viously identified with genetic defects leading to Mn dys-
regulation (Table 1).
Biochemical studies
Biochemical studies in the proband detected normal full
blood count, liver function, Fe metabolism, Zn, Se and
copper (Cu) concentrations in plasma. We also found el-
evated plasma Mn (10.5 μg/L, RV: 0.4–0.9 μg/L) and ex-
tremely elevated CSF Mn concentrations (34 μg/L, RV:
0.5–1.7 μg/L).
MRI analysis
Brain MRI of the patient at 11 months showed a symmet-
rical high-T1 and low T2 signal in both the pallidum and
dentate nuclei. White matter signal intensity of the cere-
brum, cerebellum and brainstem was also very high in T1
(Fig. 1a). Follow-up MRI at 10 years showed persistent
T1-hyperintensity of the globi pallidi, volume loss, gliosis
and atrophy of the dentate nuclei and moderate atrophy
Table 1 Characteristics of patients with SLC30A10, SLC39A14, and SLC39A8 mutations (Continued)
Phenotypes SLC30A10 SLC39A14 SLC39A8
Early-onset dystonia, polycythemia
and hepatopathy, adult-onset
parkinsonism and spastic paraparesis
Rapidly progressive childhood-
onset parkinsonism-dystonia
Type II congenital disorder of
glycosylation with Leigh syndrome
and autosomal recessive intellectual
disability with cerebellar atrophy
Other Treatments Iron oral supplementation 19
Zinc, vitamins C and D supplementation,
manganese free-diet, L-dopa, pramiprexole
and intratechal baclofen
Galactose, manganese, CoQ10, thiamine,
pyridoxine and glucocorticoid
F Female, M Male, Mn Manganese, IQR Interquartile range, RV Reference values
aDysmorphic features include a broad forehead, mid-face hypoplasia, small jaw, hirsutism, anteverted nostrils, thin lips and a smooth philtrum
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of cerebellar folia. Moreover, quantitative assessments of
the PI was significantly higher in the patient at age
11 months, 8 and 10 years as compared to nine age-
matched controls (U = 0.000; p = 0.009, Mann-Whitney U
test). We also observed slightly increased signal intensity
over time (Fig. 1b).
Genetic analysis
We identified a homozygous missense variant (c.311G >T;
p.Ser104Ile) in exon 3 of SLC39A14 (NM_001128431),
which was confirmed by Sanger sequencing in both the pa-
tient and his affected brother. Both parents were heterozy-
gous carriers of this variant (Fig. 2). Unfortunately, DNA
samples from three unaffected siblings were not available
for the analysis. This novel variant was not found in
HGMD, dbSNP, 1000 Genome project, ExAC database or
CIBERER Spanish Variant Server. This variant affected a
highly conserved amino acid residue, located in the
N-terminus extracellular loop, studied by UCSC
browser and Clustal Omega software and it was cate-
gorized as pathogenic by SIFT (0.002), PROVEAN
(−3.03) and Mutation Taster (142), and as possibly
damaging by PolyPhen-2 (0.664).
Treatment
Following genetic confirmation, we instigated com-
passionate treatment with the Mn chelator,
Na2CaEDTA, 1 g/m2/day in two divided oral doses
for a five-day course. This protocol was initially
proposed for lead intoxication and has more
recently been used in patients with SLC30A10 and
SLC39A14 deficiency [14, 15]. No clinical side
effects were recorded during the administration. On
the fifth day, we observed a reduction of plasma
Mn (from 10.5 to 4.5 μg/L, 57% reduction, RV: 0.4–
0.9 μg/L), Zn (from 1260 to 381 ng/L, 69.8% reduc-
tion, RV: 628–1200 ng/L) and Se (from 84 to 58 ng/
L, 31.5% reduction, RV: 67–104 ng/L) (Fig. 3), and
therefore he was supplemented with Zn acetate
(10 mg/day) and Se (50 mg every 2 days). There
was also a mild decrease in plasma Cu and Fe but
values remained within the normal range. Two
weeks after treatment, the family referred worsening
of cervical dystonia, irritability and sleep difficulties,
which improved with incremental doses of diaze-
pam. The family decided to discontinue chelation




Fig. 1 Radiological findings from the patient. a: Brain MRI of the patient at 11 months (first line) shows a high-T1 and low T2 signal in the pallidi
and dentate nuclei. MRI at 10 years (second line) shows persistent T1-hyperintensity of the globi pallidi, volume loss, gliosis and atrophy of the
dentate nuclei and moderate atrophy of cerebellar folia. b: Distribution of individual PI scores in patient and controls
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Discussion
We present two siblings with a homozygous missense
variant in SLC39A14, manifesting a rapidly progressive
generalized dystonia in infancy and hypermanganese-
mia, similar to a cohort of eight SLC39A14 mutated
children reported [15]. Our patient did not show poly-
cythemia or liver disease, as observed in SLC30A10-
deficient patients (Table 1). We measured plasma and
CSF Mn, both showing very high values comparing to
our control patients and literature reference ranges
[29]. Importantly, Mn values were 3-fold higher in CSF
than in plasma; in keeping with the finding that brain
Mn levels are four to 20-fold higher in slc39a14 mutant
zebra fish [15] and knockout mice [4, 6] compared to
wild-type. Our findings support the hypothesis that
brain is likely to be the main organ of Mn deposition in
SLC39A14 deficiency.
Previously, Chang et al., 2009 reported a correlation
between pallidal index (PI) and plasma Mn concentra-
tions of 43 manganese-exposed welders and concluded
that high PI might be attributed to Mn brain deposition
[30]. We used PI to quantify pallidal Mn accumulation
in our patient, and observed significantly higher values
than in controls. Furthermore, our patient had higher PI
values compared to occupationally Mn exposed workers
[31]. These values slightly increased over time, suggest-
ing the relentless pallidal accumulation of Mn in
SLC39A14 deficiency.
Fig. 2 The figure shows segregation of the novel variant by Sanger sequencing in the index case and family members. Footnote: The proband is
marked with an arrow. The consanguinity is represented by a double line. Filled and unfilled symbols indicate affected and unaffected individuals,
respectively. The parents are represented as a carrier status
Fig. 3 Biochemical analysis before and after treatment. Footnote: Graph shows a reduction of plasma Mn, Zn and Se five days after Na2CaEDTA therapy
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Na2CaEDTA is a chelating agent that combines with
metal ions to form stable and soluble complexes that are
excreted in the urine. It ameliorated dystonia and parkin-
sonism in SLC30A10 mutated patients [18, 22], and its
efficacy proved to be persistent over time is some cases
with long-term follow-up [22, 32]. More recently, two
SLC39A14 patients received Na2CaEDTA, one, given
chelation early in the disease course showed clinical im-
provement, whereas the other (older) patient continued to
deteriorate despite treatment [15]. Interestingly, two
SLC39A14 KO mice models recently demonstrated a
positive effect with two different chelators: a zinc-
supplemented diet significantly decreased brain Mn
uptake [4], and the metal chelator Na2CaEDTA reduced
serum Mn levels and rescued motor deficits [10].
The administration of Na2CaEDTA in our patient led
to the reduction of not only plasma Mn values, but also
Se and Zn, which are cofactors of important enzymes
such as SOD and selenoproteins, and hence, they were
supplemented in our patient. Even though Se is not a
cation, the decrease might be an effect of EDTA on renal
tubules during chelation therapy [33]. Unfortunately,
worsening of dystonia resulted in discontinuation of
Na2CaEDTA and the long-term efficacy of this treatment
could not be tested in this patient.
Conclusions
In this study we present two infants presenting with dys-
tonia and hypermanganesemia caused by a homozygous
missense variant in SLC39A14, a recently recognized
gene involved in Mn homeostasis in humans, thus
expanding the very few descriptions of this disorder. We
also report for the first time the elevation of Mn in CSF
of SLC39A14 mutated patients, supporting the hypoth-
esis that brain is an important organ of Mn deposition
in SLC39A14-related disease. The measurement of PI
values on MRI is a non-invasive method that may help
monitor Mn pallidal deposition over time. Finally, we
propose that patients with inherited defects of manga-
nese transport should be initially treated with low doses
of Na2CaEDTA followed by gradual dose escalation,
together with a close monitoring of blood trace elements
in order to avoid side effects.
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